Flutter Entertainment to Buy 56% of Brazil's NSX Group for $350 Million
By Ian Walker
Flutter Entertainment is creating a new Brazilian business through the acquisition of a 56% stake in Brazil's NSX Group for $350 million and a 56% share of Betfair Brazil.
The parent company of FanDuel, Betfair and other gaming and gambling brands said Friday that the deal is part of its strategy to invest in leadership positions in international markets. It expects the deal to close in the second quarter of next year, conditional upon the usual regulatory clearances.
Flutter said it would be able to increase its shareholding in the new business through a put and call arrangement in year five and ten after completion of the initial deal.
"We believe that combining the extensive local expertise of the NSX team, our existing Betfair business and the power of the Flutter Edge, will create a compelling opportunity to capitalize on the growth opportunity in Brazil which presents an exciting runway of future growth," Chief Executive Peter Jackson said.
NSX, which has a portfolio of brands including Betnacional, is expected to generate $256 million of revenue and adjusted earnings before interest, taxes, depreciation and amortization of approximately $34 million in 2024, Flutter said.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
September 13, 2024 02:40 ET (06:40 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks